Accelerate Diagnostics Q1 EPS $(1.70) Misses $(1.40) Estimate, Sales $2.81M Miss $3.35M Estimate
Portfolio Pulse from Benzinga Newsdesk
Accelerate Diagnostics (NASDAQ:AXDX) reported Q1 losses of $(1.70) per share, missing the analyst consensus estimate of $(1.40) by 21.43%. This is a 32% increase over losses from the same period last year. The company also reported quarterly sales of $2.81 million, missing the analyst consensus estimate of $3.35 million by 16.06%. This is a 4.94% decrease over sales from the same period last year.
August 10, 2023 | 9:20 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Accelerate Diagnostics reported Q1 losses and sales that missed analyst estimates. This could negatively impact the company's stock in the short term.
Accelerate Diagnostics reported higher than expected losses and lower than expected sales for Q1. This underperformance compared to analyst estimates could lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100